Tomorrow’s quantitation: increased robustness for quantitation of immunosuppressant drugs in blood with the TSQ Fortis MS for clinical research

Importance of the Topic

Immunosuppressant drugs such as cyclosporin A, tacrolimus, sirolimus and everolimus are critical in transplant medicine and autoimmune disease management. Accurate and robust quantitation in whole blood supports therapeutic drug monitoring, dose adjustment and patient safety. The combination of ultra-high performance liquid chromatography (UHPLC) and triple quadrupole mass spectrometry (QqQ MS) delivers the sensitivity and selectivity required for reliable clinical research assays.

Objectives and Scope of the Study

This work aimed to develop and validate a high-throughput, reproducible UHPLC-MS/MS workflow for quantifying key immunosuppressants in whole blood. Specific goals included:

• Achieving low limits of quantitation with robust selectivity.
• Demonstrating consistent performance over extended sample sequences (over 2,000 injections).
• Evaluating system robustness across daily maintenance operations.

Methodology and Instrumentation

Sample preparation involved protein precipitation of whole blood calibrators, controls and matrix blanks using a zinc sulfate/methanol solution containing internal standards (cyclosporin D and ascomycin). After vortexing, refrigeration and centrifugation, the supernatant was injected onto the UHPLC.

• UHPLC system: Thermo Scientific Vanquish Flex Binary UHPLC
• Analytical column: Hypersil GOLD C8, 50 × 2.1 mm, 5 µm, at 75 °C
• Mobile phases: 10 mM ammonium formate + 0.1% formic acid in water (A) and methanol (B); 3 min gradient at 0.8 mL/min
• MS detector: Thermo Scientific TSQ Fortis triple quadrupole with positive heated electrospray ionization (HESI)
• Data processing: Thermo Scientific TraceFinder 4.1 software

Main Results and Discussion

Robustness: Over six consecutive days, each sequence of ~350 injections (total 2,077 injections) maintained stringent accuracy and precision criteria. Mid-level quality controls showed RSDs of 4% for cyclosporin A, 6% for everolimus and sirolimus, and 5% for tacrolimus. Performance remained stable before and after ion transfer tube cleaning without system venting.

Linearity: Calibration curves for all analytes exhibited excellent linearity across their respective ranges (approximately 2–60 µg/L for most, up to 1,700 µg/L for cyclosporin A), with back-calculated concentrations within ±20% of theoretical values over six days.

Chromatographic Stability: Representative chromatograms on day 6 showed consistent peak shape and signal intensity for all immunosuppressants both pre- and post-maintenance, demonstrating workflow robustness.

Benefits and Practical Applications

The developed method offers:

• High throughput: 3-minute cycle time per sample supports large clinical studies.
• Reproducible quantitation: Low inter-day variability ensures reliable therapeutic monitoring.
• Minimal downtime: User-level maintenance (ion transfer tube cleaning) preserves performance without full system venting.

Future Trends and Potential Applications

Continued advances in UHPLC and QqQ MS technology will further enhance throughput and sensitivity. Integration with automated sample preparation platforms and real-time data analytics could streamline clinical workflows. Emerging ionization sources and microflow LC may reduce solvent consumption and expand the range of measurable biomarkers.

Conclusion

A rapid, robust UHPLC-MS/MS method for quantifying four immunosuppressants in whole blood was demonstrated using the Vanquish Flex and TSQ Fortis system. The assay fulfilled stringent precision, accuracy and linearity requirements, maintained stability over 2,000+ injections and withstood routine maintenance without performance loss. This workflow is well suited for high-volume clinical research and therapeutic drug monitoring applications.